JPRN-jRCT2080221683已完成3 期
A long-term study of DSP-5423 in pediatric patients with schizophrenia
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 106
研究概览
简要总结
We investigated the safety and efficacy of DSP-5423 4 to 24 mg / day for 52 weeks in pediatric schizophrenia subjects. The effectiveness of DSP-5423 was maintained even after long-term administration for schizophrenia in children, and there is no concern about safety and peculiar in children were observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who completed the confirmatory study etc.
排除标准
- •Patients who fall under a contraindication listed in the LONASEN package insert.
- •Patients with Parkinson disease etc.
研究者
相似试验
已完成
3 期
ong-term Study of DSP-5423P in Patients with SchizophreniaSchizophreniaJPRN-jRCT2080222713Sumitomo Dainippon Pharma. Co., Ltd.200
已完成
3 期
Long-term Study of DSP-5423P in Patients With SchizophreniaSchizophreniaNCT02335658Sumitomo Pharma Co., Ltd.200
已完成
3 期
Confirmatory study of DSP-5423 in pediatric patients with schizophrenia.SchizophreniaJPRN-jRCT2080221682Sumitomo Dainippon Pharma Co., Ltd.151
已完成
3 期
Confirmatory Study of DSP-5423P in Patients With SchizophreniaSchizophreniaNCT02287584Sumitomo Pharma Co., Ltd.580
已完成
3 期
Confirmatory Study of DSP-5423P in Patients with SchizophreniaSchizophreniaJPRN-jRCT2080222637Sumitomo Dainippon Pharma Co., Ltd.580